Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: Serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment

European Journal of Haematology

Volumn 94, Issue 5, 2015, Pages 404-412

  Chirico, Valeria ^a   Rigoli, Luciana ^a   Lacquaniti, Antonio ^a   Salpietro, Vincenzo ^a   Piraino, Basilia ^a   Amorini, Maria ^a   Salpietro, Carmelo ^a   Arrigo, Teresa ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Endocrinopathies; Ferritin; Hypothyroidism; Iron chelation therapy; Magnetic resonance imaging; Thalassemia

Indexed keywords

DEFEROXAMINE MESYLATE; FERRITIN; GLUCOSE; HEMOGLOBIN; BIOLOGICAL MARKER; IRON; IRON CHELATING AGENT;

ADULT; ARTICLE; BLOOD TRANSFUSION; BONE METABOLISM; CARDIOVASCULAR MAGNETIC RESONANCE; CHELATION THERAPY; CHOLELITHIASIS; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENDOCRINE DISEASE; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; HYPOGONADISM; HYPOPARATHYROIDISM; HYPOTHYROIDISM; IMPAIRED GLUCOSE TOLERANCE; IRON CHELATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NEPHROLITHIASIS; OSTEOPOROSIS; POLYENDOCRINOPATHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SPLENECTOMY; SYSTOLIC BLOOD PRESSURE; THALASSEMIA INTERMEDIA; THALASSEMIA MAJOR; ADOLESCENT; ADVERSE EFFECTS; BETA-THALASSEMIA; BLOOD; COMORBIDITY; HEART MUSCLE; ITALY; LIVER; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROPORTIONAL HAZARDS MODEL;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BIOMARKERS; BLOOD TRANSFUSION; CHELATION THERAPY; COMORBIDITY; FEMALE; FERRITINS; HUMANS; HYPOGONADISM; HYPOTHYROIDISM; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; ITALY; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; OSTEOPOROSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; ROC CURVE;

EID: 84926456066     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12444     Document Type: Article

References (23)

1. Fung EB, Harmatz PR, Lee PD, Milet M, Bellevue R, Jeng MR, Kalinyak KA, Hudes M, Bhatia S, Vichinsky EP, Multi-Centre Study of Iron Overload Research Group. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol 2006;135:574-82.
2. Walter PB, Macklin EA, Porter J, et al. Inflammation and oxidant-stress in b-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica 2008;93:817-25.
3. Karimi M, Ghiam AF, Hashemi A, Alinejad S, Soweid M, Kashef S. Bone mineral density in beta-thalassemia major and intermedia. Indian Pediatr 2007;44:29-32.
4. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with β thalassaemia. Br J Haematol 2004;127:127-39.
5. Toumba M, Skordis N. Osteoporosis syndrome in thalassaemia major: an overview. J Osteoporos 2010;2010:537-673.
6. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo controlled, double-blind trial of the effect of combined therapy with Deferoxamine and Deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007;115:1876-84.
7. Chirico V, Lacquaniti A, Salpietro V, Luca N, Ferraù V, Piraino B, Rigoli L, Salpietro C, Arrigo T. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. Eur J Endocrinol 2013; 169:785-93.
8. Argyropoulou MI, Astrakas L. MRI evaluation of tissue iron burden in patients with beta-thalassaemia major. Pediatr Radiol 2007;37:1191-200.
9. Carpenter JP, He T, Kirk P, et al. On T2* magnetic resonance and cardiac iron. Circulation 2011;123:1519-28.
10. Pennell DJ. T2* magnetic resonance and myocardial iron in thalassemia. Ann N Y Acad Sci 2005;1054:373-8.
11. Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, Nelson MD, Coates TD. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005;106:1460-5.
12. Cappellini M, Cohen A, Eleftheriou A, Piga A, Porter J. Endocrine complications in thalassaemia major. In: Thalasemia International federation. Guidelines for the clinical management of Thalassemia, 1st edn. Nicosia, Cyprus: TIF, 2000; 41-9.
13. Aydinok Y, Bayraktaroglu S, Yildiz D, Alper H. Myocardial iron loading in patients with thalassemia major in Turkey and the potential role of splenectomy in myocardial siderosis. J Pediatr Hematol Oncol 2011;33:374-8.
14. Khalifa AS, Salem M, Mounir E, El-Tawil MM, El-Sawy M, Abd Al-Aziz MM. Abnormal glucose tolerance in Egyptian beta-thalassemic patients: possible association with genotyping. Pediatr Diabetes 2004;5:126-32.
15. Akcay A, Salcioglu Z, Oztarhan K, Tugcu D, Aydogan G, Ayaz NA, Bornaun H, Sen HS, Akici F, Akdana B. Cardiac T2* MRI assessment in patients with thalassaemia major and its effect on the preference of chelation therapy. Int J Hematol 2014; 99: 706-13.
16. Koonrungsesomboon N, Chattipakorn SC, Fucharoen S, Chattipakorn N. Early detection of cardiac involvement in thalassemia: From bench to bedside perspective. World J Cardiol 2013; 5:270-9.
17. Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011;364:146-56.
18. Mahachoklertwattana P, Chuansumrit A, Sirisriro R, Choubtum L, Sriphrapradang A, Rajatanavin R. Bone mineral density, biochemical and hormonal profiles in suboptimally treated children and adolescents with beta-thalassaemia disease. Clin Endocrinol (Oxf) 2003;58:273-9.
19. Portincasa P, Moschetta A, Berardino M, Di-Ciaula A, Vacca M, Baldassarre G, Pietrapertosa A, Cammarota R, Tannoia N, Palasciano G. Impaired gallbladder motility and delayed orocecal transit contributed to pigment gallstone and biliary sludge formation in b-thalassemia major adults. World J Gastroenterol 2004;10:2382-90.
20. Lotfi M, Keramati P, Assdsangabi R, Nabavizadeh SA, Karimi M. Ultrasonographic assessment of the prevalence of cholelithiasis and biliary sludge in beta-thalassemia patients in Iran. Med Sci Monit 2009;15:398-402.
21. Wong P, Fuller PJ, Gillespie MT, Kartsogiannis V, Strauss BJ, Bowden D, Milat F. Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures. Osteoporos Int 2013;24:1965-71.
22. Ricchi P, Ammirabile M, Costantini S, Di Matola T, Spasiano A, Genna ML, Cinque P, Prossomariti L. Splenectomy is a risk factor for developing hyperuricemia and nephrolithiasis in patients with thalassemia intermedia: a retrospective study. Blood Cells Mol Dis 2012;49:133-5.
23. Taher AT, Musallam KM, Cappellini MD. Thalassaemia intermedia: an update. Mediterr J Hematol Infect Dis 2009;1:e2009004.